Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa

被引：15

作者：

Mullane, Elias M. ^{[1
]}

Avery, Lindsay M. ^{[1
]}

Nicolau, David P. ^{[1
,2
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06115 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 03期

关键词：

Pseudomonas aeruginosa; WCK; 5222; beta-lactams; carbapenem resistant; gradient diffusion; synergy;

D O I：

10.1128/AAC.01669-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of WCK 5222 (cefepime-zidebactam) was compared to that of several available combination therapies among 30 clinical carbapenem-resistant Pseudomonas aeruginosa (CRP) strains using gradient diffusion strips. The combinations included nonsusceptible beta-lactams (cefepime, ceftolozane-tazobactam, and meropenem) with amikacin and fosfomycin. WCK 5222 MICs ranged from 2 to 32 mg/liter, and 97% were <= 16 mg/liter, while 105/146 (72%) combinations demonstrated inhibition below established susceptibility breakpoints. WCK 5222 monotherapy may be preferred over the combinations assessed for CRP infections.

引用

页数：4

共 14 条

[1] Single β-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility [J].

Abuhussain, Safa S. Almarzoky ;

Sutherland, Christina A. ;

Nicolau, David P. .

INFECTIOUS DISEASES, 2020, 52 (01) :33-38

[2]

[Anonymous], 2019, M100 CLSI

[3] Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory [J].

Avery, Lindsay M. ;

Nicolau, David P. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (08) :2264-2265

[4] Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals [J].

Castanheira, Mariana ;

Doyle, Timothy B. ;

Smith, Caitlin J. ;

Mendes, Rodrigo E. ;

Sader, Helio S. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) :2588-2595

[5] Is double coverage of gram-negative organisms necessary? [J].

Johnson, Sarah J. ;

Ernst, Erika J. ;

Moores, Kevin G. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (02) :119-124

[6]

Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353

[7]

Monogue ML, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00233-19, 10.1128/aac.00233-19]

[8] Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactann Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234 [J].

Papp-Wallace, Krisztina M. ;

Nguyen, Nhu Q. ;

Jacobs, Michael R. ;

Bethel, Christopher R. ;

Barnes, Melissa D. ;

Kumar, Vijay ;

Bajaksouzian, Saralee ;

Rudin, Susan D. ;

Rather, Philip N. ;

Bhaysar, Satish ;

Ravikumar, Tadiparthi ;

Deshpande, Prasad K. ;

Patil, Vijay ;

Yeole, Ravindra ;

Bhagwat, Sachin S. ;

Patel, Mahesh V. ;

van den Akker, Focco ;

Bonomo, Robert A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (09) :4067-4086

[9]

Puzniak L, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/aac.02564-18, 10.1128/AAC.02564-18]

[10] Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin [J].

So, Wonhee ;

Shurko, James ;

Galega, Ralph ;

Quilitz, Rod ;

Greene, John N. ;

Lee, Grace C. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (01) :269-271

← 1 2 →